Abetimus

Identification

Name
Abetimus
Accession Number
DB06662
Type
Biotech
Groups
Investigational
Biologic Classification
Nucleic Acid Based Therapies
Oligonucleotides
Description

Abetimus is an immunosuppressant developed by La Jolla Pharmaceutical, who applied for marketing authorisations in the mid-2000s, but the drug was never marketed in the US or in Europe.

Synonyms
Not Available
Product Ingredients
IngredientUNIICASInChI Key
Abetimus sodiumF5Y7739G6U169147-32-4Not applicable
International/Other Brands
Riquent
Categories
UNII
P3UVQ22SHK
CAS number
167362-48-3

Pharmacology

Indication

Investigated for use/treatment in kidney disease and systemic lupus erythematosus.

Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteraction
AdalimumabThe risk or severity of adverse effects can be increased when Adalimumab is combined with Abetimus.
AlclometasoneThe risk or severity of adverse effects can be increased when Abetimus is combined with Alclometasone.
AldesleukinThe risk or severity of adverse effects can be increased when Abetimus is combined with Aldesleukin.
AlemtuzumabThe risk or severity of adverse effects can be increased when Alemtuzumab is combined with Abetimus.
AmcinonideThe risk or severity of adverse effects can be increased when Abetimus is combined with Amcinonide.
AmsacrineThe risk or severity of adverse effects can be increased when Amsacrine is combined with Abetimus.
AnakinraThe risk or severity of adverse effects can be increased when Anakinra is combined with Abetimus.
Anthrax immune globulin humanThe risk or severity of adverse effects can be increased when Abetimus is combined with Anthrax immune globulin human.
Antithymocyte immunoglobulin (rabbit)The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Abetimus.
Bacillus calmette-guerin substrain connaught live antigenThe risk or severity of adverse effects can be increased when Abetimus is combined with Bacillus calmette-guerin substrain connaught live antigen.
Food Interactions
Not Available

References

General References
  1. Authors unspecified: Abetimus: Abetimus sodium, LJP 394. BioDrugs. 2003;17(3):212-5. [PubMed:12749759]
  2. Wallace DJ: Clinical and pharmacological experience with LJP-394. Expert Opin Investig Drugs. 2001 Jan;10(1):111-7. [PubMed:11116284]
External Links
Wikipedia
Abetimus
ATC Codes
L04AA22 — Abetimus

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
2WithdrawnDiagnosticSystemic Lupus Erythematosus (SLE)1
3CompletedTreatmentAutoimmune Diseases / Immunologic Diseases / Lupus Glomerulonephritis / Nephritis, Lupus / Systemic Lupus Erythematosus (SLE)1
3TerminatedTreatmentLupus Erythematosus, Systemic / Nephritis, Lupus1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available

Taxonomy

Classification
Not classified

Drug created on March 19, 2008 10:46 / Updated on August 02, 2018 05:38